H4

Kanazawa University research: Biochemical tails tell a story

Retrieved on: 
Wednesday, April 24, 2024
Protein, Histone, Map, X-ray crystallography, Animal, AFM, Motion, Plant, H3, Nano Letters, Lens, DNA, Kanazawa University, Nucleosome, Gene expression, H4, H2B, Microscope

Of particular importance in these processes are the end structures, or tails, of the histones.

Key Points: 
  • Of particular importance in these processes are the end structures, or tails, of the histones.
  • Detailed studies, and especially visualizations, of nucleosome dynamics are crucial for better understanding the role of histone tails.
  • Mikihiro Shibata from Kanazawa University and colleagues have now succeeded in making video recordings of tail-less nucleosomes, showing that the absence of histone tails significantly increases a nucleosome's dynamic activity.
  • Researchers at Nano Life Science Institute (WPI-NanoLSI), Kanazawa University have in recent years developed HS-AFM further, so that it can be applied to study biochemical molecules and biomolecular processes in real-time.

Kanazawa University research: Biochemical tails tell a story

Retrieved on: 
Wednesday, April 24, 2024
Protein, Histone, Map, X-ray crystallography, Animal, AFM, Motion, Plant, H3, Nano Letters, Lens, DNA, Kanazawa University, Nucleosome, Gene expression, H4, H2B, Microscope

Of particular importance in these processes are the end structures, or tails, of the histones.

Key Points: 
  • Of particular importance in these processes are the end structures, or tails, of the histones.
  • Detailed studies, and especially visualizations, of nucleosome dynamics are crucial for better understanding the role of histone tails.
  • Mikihiro Shibata from Kanazawa University and colleagues have now succeeded in making video recordings of tail-less nucleosomes, showing that the absence of histone tails significantly increases a nucleosome's dynamic activity.
  • Researchers at Nano Life Science Institute (WPI-NanoLSI), Kanazawa University have in recent years developed HS-AFM further, so that it can be applied to study biochemical molecules and biomolecular processes in real-time.

BEDGEAR Unveils Revolutionary Split Head Line: A Personalized Sleep System for Couples

Retrieved on: 
Thursday, October 12, 2023
USB, M3, Queens Kings, Flex, H4, Sheet, Smartphone, Co-sleeping, Sleep, Longevity, Head, Snoring, Relaxation, Compromise, Reading, Hotel, Pharmaceutical industry, Tutoring

Engineered for intimacy and comfort, BEDGEAR's Split Head design minimizes separation, delivering an uninterrupted sleeping experience unlike other Split Head mattresses on the market.

Key Points: 
  • Engineered for intimacy and comfort, BEDGEAR's Split Head design minimizes separation, delivering an uninterrupted sleeping experience unlike other Split Head mattresses on the market.
  • BEDGEAR's Split Head Sleep System addresses the diverse needs of couples, promoting better sleep and, consequently, overall well-being.
  • The BEDGEAR Split Head Sleep System line is available for purchase at select retailers and on BEDGEAR's official website now.
  • For more information about BEDGEAR and its revolutionary Split Head Sleep System, please visit www.bedgear.com

BrainsWay Announces Publication of Three New Deep TMS Research Publications

Retrieved on: 
Thursday, August 3, 2023
Medical Affairs Bureau, Suds, TMS, Brainsway, Isabella Tree, Transcranial magnetic stimulation, Innovation, Research, H1, AUD, The Journal of Clinical Psychiatry, Journal, Publication, Patient, Deep, TASE, FDA, Smoking, Mental health, Caregiver, Safety, Medical device, Pharmaceutical industry, H4, List of MDPI academic journals

and JERUSALEM, Aug. 03, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced three recent publications highlighting its Deep Transcranial Magnetic Stimulation (Deep TMS™) in leading peer-reviewed medical journals.

Key Points: 
  • and JERUSALEM, Aug. 03, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced three recent publications highlighting its Deep Transcranial Magnetic Stimulation (Deep TMS™) in leading peer-reviewed medical journals.
  • Two of the publications enhance understanding of the safety profile of TMS.
  • BrainsWay Deep TMS™ for smoking addiction represents the only FDA-cleared TMS solution for any addiction.
  • The publication highlights preliminary research of Deep TMS in various other addictions, and underscores the need for further randomized controlled clinical trials in these difficult-to-treat conditions.

BEDGEAR Announces its Newest Bedding Innovations with Groundbreaking Modular Design and Showcases Sustainability-Themed Retail Theater for the 2023 Las Vegas Market

Retrieved on: 
Thursday, July 27, 2023
First Time, Floor, M3, Crown, Flex, H4, Night, Environment, Consumer electronics, Hotel, World Market Center Las Vegas

In addition to the new offerings, the brand will showcase a sustainability-themed retail theater display at the bi-annual Summer 2023 Las Vegas Market .

Key Points: 
  • In addition to the new offerings, the brand will showcase a sustainability-themed retail theater display at the bi-annual Summer 2023 Las Vegas Market .
  • Las Vegas Market attendees will get a sneak peek look at the newest product innovations, rolling out later this summer which continues BEDGEAR's mission to provide consumers with personalized and modular sleep products with sustainability in mind.
  • BEDGEAR's Retail theater will also give attendees an in-person look at a handful of their most popular pillows and mattresses.
  • To check out the retail theater and the new BEDGEAR products at Las Vegas Market, visit the BEDGEAR' showroom at the Las Vegas Design Center located in Building B on the 11th Floor, Suite B-1100.

VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

Retrieved on: 
Monday, May 1, 2023
Research, H4, BET, H3, Attention deficit hyperactivity disorder predominantly inattentive, BD2, BD1, Therapy, Thrombocytopenia, Gene, Safety, Tay, Pharmaceutical industry, IND

BRIDGEWATER, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the selection of a development candidate for its oral BD2-selective bromodomain and extra-terminal (“BET”) inhibitor program, VYN202, for the treatment of immuno-inflammatory conditions. The lead candidate was selected by VYNE from a library of BD2-selective BET inhibitors that VYNE exclusively licensed from Tay Therapeutics following the receipt of a robust package of preclinical data, including encouraging results from well-validated animal models in various autoimmune disorders. VYNE also obtained rights to several other BD2-selective BET inhibitor compounds with attractive molecular profiles that the Company may develop, at its discretion, in the future.

Key Points: 
  • BRIDGEWATER, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the selection of a development candidate for its oral BD2-selective bromodomain and extra-terminal (“BET”) inhibitor program, VYN202, for the treatment of immuno-inflammatory conditions.
  • The lead candidate was selected by VYNE from a library of BD2-selective BET inhibitors that VYNE exclusively licensed from Tay Therapeutics following the receipt of a robust package of preclinical data, including encouraging results from well-validated animal models in various autoimmune disorders.
  • VYNE also obtained rights to several other BD2-selective BET inhibitor compounds with attractive molecular profiles that the Company may develop, at its discretion, in the future.
  • As epigenetic readers, BET proteins are super-enhancers of gene transcription that drive the hyperactive production of many pro-inflammatory proteins that characterize autoimmune and autoinflammatory diseases.

Ecoppia’s H4 Robotic Solar PV Cleaner Awarded Top Product of the Year by Environment + Energy Leader Awards

Retrieved on: 
Wednesday, July 20, 2022
Mobile, Wireless, Internet, Other Energy, Utilities, Electronic Design Automation, Robotics, Data Management, Alternative Energy, Energy, Technology, Environment, Other Technology, PV, Multimedia, Federal Ministry for Climate Action, Environment, Energy, Mobility, Innovation and Technology, H4, O&M, Program, Water, Environment, Ernst & Young Entrepreneur of the Year Award, Energy, TASE, Safety, Renewable energy

Ecoppia (TASE: ECPA), the pioneer and world leader in robotic cleaning solutions for solar PV, has won the Top Product of the Year Award for their H4 robot in the elite Environment + Energy Leader Awards program.

Key Points: 
  • Ecoppia (TASE: ECPA), the pioneer and world leader in robotic cleaning solutions for solar PV, has won the Top Product of the Year Award for their H4 robot in the elite Environment + Energy Leader Awards program.
  • Receiving this prestigious award demonstrates that industry experts see the H4 as an exemplary solution in the fields of energy and environmental management.
  • View the full release here: https://www.businesswire.com/news/home/20220719005586/en/
    Ecoppia wins Top Product of the Year Award by Environment and Energy for the H4 robotic cleaning solution (Photo: Ecoppia)
    The autonomous H4 robotic cleaning solution addresses scalability and remote management for large scale solar PV sites.
  • To further bolster the solutions smart, effective, and safe features, the H4 introduces helix technology into PV cleaning.

Lumavate Launches Content Management System Making it Simple for Organizations to Manage and Reuse Various Types of Content

Retrieved on: 
Wednesday, July 13, 2022
Indiana University Health, Software as a service, LinkedIn, Organization, DXPS, CEO, Roche, DXP, CMS, BD, Cummins, Twitter, Television, Mobile phone, Online shopping, H4, H3

CARMEL, Ind. , July 13, 2022  /PRNewswire-PRWeb/ --

Key Points: 
  • Lumavate , a SaaS company making it easy for everyone to create powerful digital experiences, announced the launch of its content management system (CMS).
  • Lumavate Content makes it simple for organizations to manage and reuse various types of content across an unlimited number of digital experiences.
  • This functionality also seamlessly integrates with all of the existing 150+ design elements, making it simple for users to take advantage of Lumavate Content.
  • Additionally, any updates made to items in Lumavate Content are automatically updated in the digital experiences using the content.

DGAP-News: LPKF closes 2021 financial year in line with forecast and records strong order intake

Retrieved on: 
Friday, April 1, 2022
Saskatchewan River Sturgeon Management Board, Electronics, Investment, Marketing, Growth, Board, Miniaturization, News, Supervisory board, ESG, DGAP, Solar, Environment, Executive Office of the President of the United States, CEO, EBIT, Technology, H4, Tax, Solution, Development, EUR, Acquisition, Garbsen, Annual, Security (finance), Film, Renewable energy, Group

Despite careful planning and a flexible response to changing conditions, LPKF was unable to escape the effects of this environment.

Key Points: 
  • Despite careful planning and a flexible response to changing conditions, LPKF was unable to escape the effects of this environment.
  • The order backlog has reached EUR 62.6 million at the end of the year, a 64 % increase over the previous year.
  • CFO Christian Witt explained: "We had set ourselves ambitious financial targets for 2021, which we did not achieve despite all our efforts and precautionary measures.
  • With the high order backlog in the Group, we are well positioned to achieve strong growth in 2022.

Akari Therapeutics Announces New Data Supporting Use of Drug Candidate Votucalis Targeting Difficult to Treat Pain and Itch

Retrieved on: 
Wednesday, March 9, 2022
Nasdaq, Atopic dermatitis, GMP, Lung, Psoriasis, Mouse, Private Securities Litigation Reform Act, Drug development, Leukotriene B4, Risk, TMA, Neuropathic pain, Chronic pain, Inflammation, Research, H4, U.S. Securities and Exchange Commission, Therapy, FDA, Failure, Newcastle University, Annual report, Regulation of tobacco by the U.S. Food and Drug Administration, Dermatology, Itch, BP, Akari, H3, EMA, CNS, Histamine, Pain, Brain, Intellectual property, Durham University, LTB4, GLOBE, HIV disease progression rates, Newcastle University Students' Association (NUSA), Patient, G protein-coupled receptor, Security (finance), European Medicines Agency, Eye, Effectiveness, Central nervous system, COVID-19, H1, Leukotriene, SEC, Food, Program, CEO, Frontiers, Thrombotic microangiopathy, Pharmaceutical industry, Pharmacology

Activation of these receptors can induce multiple pathophysiological processes, including chronic pain, itch and inflammation.

Key Points: 
  • Activation of these receptors can induce multiple pathophysiological processes, including chronic pain, itch and inflammation.
  • The data published today were from two preclinical models of itch and pain in mice.
  • In itch, votucalis provided inhibition of histaminergic itch of around 62%, with the potential for greater reduction with higher dosing.
  • Akari's lead drug candidate, nomacopan, is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity.